Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
WILMINGTON, Del., Sept. 29, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Concordia International Corp. (NASDAQ:CXRX)?
- Did you purchase your shares between November 12, 2015 and August 12, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Concordia International Corp. (“Concordia” or the “Company”) (NASDAQ:CXRX) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Concordia between November 12, 2015 and August 12, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public: (1) that the Company was experiencing a substantial increase in market competition against the Company’s drug, Donnatal, and other products; (2) that, as a result, the Company’s financial results would suffer and the Company would be forced to suspend its dividend; and (3) that, as a result of the foregoing, Defendants’ statements about Concordia’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
If you wish to serve as lead plaintiff, you must move the Court no later than October 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Concordia during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/concordia-international-corp-cxrx.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
